secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-05-19T20:05:46+00:00
Accession:  0001683168-26-004116
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds
--------------------------------------------------------------------------------

- Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.
- Each unit includes one share (or pre-funded warrant) plus two Series C warrants exercisable at $0.50 for five years.
- Potential additional $12.0M if Series C warrants fully exercised; no assurance given.
- Net proceeds for general corporate purposes and working capital.
- Aegis Capital Corp acted as placement agent with 7% fee plus 2% expense allowance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/0001683168-26-004116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-004116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer